Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase inhibitors may prove superior to IM. Real-time quantitative polymerase chain reaction (RQ-PCR) provides an accurate measure of the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hughes, Timothy, Deininger, Michael, Hochhaus, Andreas, Branford, Susan, Radich, Jerald, Kaeda, Jaspal, Baccarani, Michele, Cortes, Jorge, Cross, Nicholas C. P., Druker, Brian J., Gabert, Jean, Grimwade, David, Hehlmann, Rüdiger, Kamel-Reid, Suzanne, Lipton, Jeffrey H., Longtine, Janina, Martinelli, Giovanni, Saglio, Giuseppe, Soverini, Simona, Stock, Wendy, Goldman, John M.
Formato: Artigo
Idioma:Inglês
Publicado em: The American Society of Hematology 2006
Assuntos:
Review in Translational Hematology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895821/
https://ncbi.nlm.nih.gov/pubmed/16522812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-01-0092
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados